Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Income from Continuing Operations: 2019-2025

Historic Income from Continuing Operations for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to -$174.1 million.

  • Avidity Biosciences' Income from Continuing Operations fell 117.13% to -$174.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$548.5 million, marking a year-over-year decrease of 95.95%. This contributed to the annual value of -$322.1 million for FY2024, which is 52.18% down from last year.
  • Per Avidity Biosciences' latest filing, its Income from Continuing Operations stood at -$174.1 million for Q3 2025, which was down 11.11% from -$156.7 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Income from Continuing Operations peaked at -$23.8 million during Q1 2021, and registered a low of -$174.1 million during Q3 2025.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$70.7 million (2024), whereas its average is -$89.1 million.
  • Data for Avidity Biosciences' Income from Continuing Operations shows a maximum YoY tumbled of 291.80% (in 2021) over the last 5 years.
  • Avidity Biosciences' Income from Continuing Operations (Quarterly) stood at -$38.5 million in 2021, then crashed by 31.07% to -$50.5 million in 2022, then declined by 19.59% to -$60.3 million in 2023, then slumped by 69.81% to -$102.5 million in 2024, then plummeted by 117.13% to -$174.1 million in 2025.
  • Its Income from Continuing Operations stands at -$174.1 million for Q3 2025, versus -$156.7 million for Q2 2025 and -$115.3 million for Q1 2025.